Navigation Links
Ohio Sales Rep's Information Launched Massive Government Investigation of Cephalon
Date:9/29/2008

Unique off-label marketing case results in $425M settlement

WASHINGTON, Sept. 29 /PRNewswire/ -- The government's investigation into Cephalon Inc.'s illegal marketing practices that culminated in today's $425,000,000 settlement and guilty plea by the pharmaceutical company began in January 2003 with a Cephalon sales representative in Ohio.

The sales representative, Bruce Boise, refused to follow company-ordered sales strategies to convince doctors to prescribe Cephalon's Actiq, Gabitril and Provigil drugs for unapproved ("off-label') uses because he was worried the sales practices were illegal and the "off-label" uses were dangerous for patients.

Boise was so concerned about Cephalon's off-label marketing that he contacted the Food and Drug Administration (FDA) to inform them of what the company was doing and then agreed to wear a wire to a company sales conference to help the government gather evidence.

The decision to report Cephalon to the FDA cost Boise his job and future employment in the pharmaceutical industry. But his information helped end Cephalon's illegal marketing practices that put patients at risk and led to today's settlement.

Cephalon Inc. (Nasdaq: CEPH), a pharmaceutical company based in Frazer, Pennsylvania, will pay the federal government and numerous states a total of $375 million to settle four "qui tam" (whistleblower) lawsuits alleging Medicare and Medicaid fraud involving the sales and marketing of Actiq, Gabitril and Provigil between 2001 and 2006. At the same time, Cephalon has agreed to plead guilty to a criminal charge involving off-label marketing of the drugs and will pay a $50 million fine.

"What makes this case unique is that it's the first time, in the absence of substantial kickbacks, that the federal government has used the False Claims Act to go after a pharmaceutical company for marketing drugs for off- label indications for which there were no credible published scientific research supporting these drugs' safety or effectiveness," said Peter W. Chatfield, a Washington, DC, attorney whose firm, Phillips & Cohen LLP, represents Boise. "Not only were these uses marketed by Cephalon not approved by the FDA, there was absolutely no literature published in any medical compendia that supported them."

The FDA approves drugs for specific uses, which are noted in the drugs' labeling. Doctors may prescribe those drugs for other "off-label" therapeutic uses, but the law prohibits drug companies from promoting drugs for uses beyond those found to be safe and effective by the FDA.

While Medicare, Medicaid and other federally funded healthcare programs often will pay for off-label use of drugs supported by credible medical research and prescribed based on the medical judgment of physicians, Cephalon's marketing efforts pushed well beyond those constraints.

Cephalon's off-label sales strategies were very effective. The government's investigation found that more than 80 percent of the sales of Provigil, Gabitril and Actiq were for off-label uses.

The FDA approved the use of Provigil to help keep awake patients with certain disorders, such as sleep apnea or shift-work sleep disorder. To boost sales, Cephalon marketed Provigil for off-label uses including fatigue associated with mental illnesses, such as schizophrenia, and children with attention deficit hyperactivity disorder, according to Boise's lawsuit.

Gabitril was approved for the treatment of partial seizures in epileptic patients. Yet Cephalon was pushing doctors to prescribe it for anxiety and insomnia, Boise's lawsuit said.

The most dangerous Cephalon drug when used for "off-label" uses is Actiq, an opioid that is approved only to treat cancer patients when their usual pain medication doesn't control "breakthrough" episodes of extreme pain. The potential side effects of Actiq include nausea, dizziness and respiratory depression, which can be life-threatening.

Boise's lawsuit says that Cephalon decided to increase Actiq's sales by marketing it for general pain treatment to internists and general practitioners - doctors who usually aren't as familiar as oncologists are with the potential dangers associated with using a prescription narcotic such as Actiq.

Boise was the first to report Cephalon's off-label marketing practices to the federal government and played a key role in the investigation. Only after he was fired and found it impossible to secure new employment in the industry because he had been blackballed did he seek counsel to file a lawsuit under the False Claims Act. The whistleblower law allows private citizens to sue companies defrauding the government and receive a reward. But by the time he hired a lawyer to represent him, nearly two years had passed since he first contacted the FDA.

In the interim, two other whistleblowers filed qui tam lawsuits making similar allegations nine months after Boise had provided extensive information to the FDA and reported Cephalon to the FDA. After he learned about the False Claims Act, Boise contacted Phillips & Cohen, which filed his qui tam lawsuit in federal district court in Philadelphia, Pennsylvania, in September 2004 on behalf of the federal government and a dozen states with similar false claims statutes. A fourth whistleblower filed a qui tam lawsuit one week later.

Today's settlement covers all four whistleblower lawsuits. The whistleblowers will receive a reward totaling $46 million for their information and the work on the case they did with their attorneys on the federal case and roughly an additional $11 million for the state cases.

"Bruce Boise sacrificed a lot to protect patients across this country," attorney Chatfield said. "But he found Cephalon's practices to be so outrageous and dangerous that he has no regrets about going to the FDA despite suffering more personal hardship than any whistleblower I have ever represented."

Chatfield praised the work of Assistant U.S. Attorney Marilyn S. May of the Eastern District of Pennsylvania and William C. Gambrell Jr. of South Carolina's Medicaid Fraud Control Unit, who coordinated the efforts of the states to evaluate losses to the Medicaid program.

Phillips & Cohen is the largest and most successful law firm that specializes exclusively in representing whistleblowers nationwide in qui tam and tax fraud cases. Qui tam cases brought by the firm's attorneys have returned more than $2 billion to the U.S. Treasury. For more information about Phillips & Cohen and whistleblower cases, see http://www.phillipsandcohen.com.


'/>"/>
SOURCE Phillips & Cohen
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Alert Alarm Michigan Seeks Employees With Inside and Outside Sales Experience
2. Ellex Commences Direct Sales in Germany
3. Medical Solutions Ranks No. 472 in the 2008 Inc. 500 with Three-Year Sales Growth of 667.8%
4. Healthcare Executive Richard Peitzmeier Returns to Phoenix as Regional Sales Director of SCAN Health Plan Arizona
5. Driving Toward Cleaner Air: July Gasoline Sales in Minnesota Decline By 9%, E85 Sales Up 16%
6. State of Ohio Recognizes Cincinnati Sub-Zero for Excellence in International Sales
7. Novis Pharmaceuticals Announces John W. Kilgour as Executive Vice-President of Sales & Marketing
8. Sales of Emerging Novel Pain Therapies Will Represent More than One-Fifth of the Total Pain Drug Market by 2023
9. Despite Bad Economy Botox Sales Are Booming
10. Kendle Delivers Record Sales, Net Service Revenues and Earnings Per Share for Second Quarter 2008
11. P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... May 25, 2016 , ... ... “Advancing Drug Development through Molecular Imaging.” The focus of ADDMI-IG will be geared ... discovery and development pipeline issues. Through ADDMI-IG WMIS will provide a platform for ...
(Date:5/25/2016)... ... May 25, 2016 , ... ... supporting the real time adjudication of medical service claims by Pharmacy Benefit Managers ... current medical claims management software. The TransactRx Cross Benefit Clearinghouse receives standard professional ...
(Date:5/25/2016)... ... ... than fifty years, we've suffered whiplash as each new scientific study seemed to contradict the ... advice – advice that was supposed to keep us healthy and slim. And what happened? ... considered to be overweight and more than 1 in 3 adults are considered to be ...
(Date:5/25/2016)... ... ... Consumer access to organic foods and grower access to food processers is about ... and other plant-based foods, will introduce the first consumer product (a new breakfast cereal) ... Organic Products. , The transitional designation means the cereal was made using at least ...
(Date:5/24/2016)... ... May 24, 2016 , ... According to an article ... people randomly assigned to reduce the amount of calories they consumed by 25% experienced ... body weight enjoyed better sleep, improved quality of life, and enhanced sexual function compared ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... Zealand , May 24, 2016 ... informatics solutions for the healthcare sector, has been named the ... Zealand Hi-Tech Awards 2016. Dr Bruce Davey ... acknowledgement for our team.  It,s really good to be recognised ... healthcare internationally. Our products are used in 35 countries around ...
(Date:5/24/2016)... May 24, 2016 Los ... terapia del mundo, introduce catéteres para la intervención ... OrbusNeich, una compañía global especializada en el suministro ... expandido su cartera incluyendo productos para tratar la ... Scoreflex™ PTA son los dispositivos de primera entrada ...
(Date:5/23/2016)... , May 23, 2016 ... Handling Equipment Market by Product (Wheelchair, Scooters, Medical ... (Bariatric Care, Critical Care, Wound), Accessories (Lifting, Transfer) ... to 2021", published by MarketsandMarkets, the patient handling ... Billion by 2021 at a CAGR of 10.5% ...
Breaking Medicine Technology: